Wang M, Sun L, Qian J, et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009;23:1320–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Lu H, Pang T, et al. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: a meta-analysis. Leuk Res. 2021;108:106605.

Article  PubMed  Google Scholar 

Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lew TE, Minson A, Dickinson M, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10:e142–54.

Article  CAS  PubMed  Google Scholar 

Ying ZT, Zheng W, Wang XP, et al. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma. Chin J Cancer. 2012;31:348–53.

Article  PubMed  PubMed Central  Google Scholar 

Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–75.

Article  CAS  PubMed  Google Scholar 

Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–60.

Article  PubMed  Google Scholar 

Hilal T, Wang Z, Almader-Douglas D, Rosenthal A, Reeder CB, Jain T. Rituximab maintenance therapy for mantle cell lymphoma: a systematic review and meta-analysis. Am J Hematol. 2018;93:1220–6.

Article  CAS  PubMed  Google Scholar 

Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.

Article  CAS  PubMed  Google Scholar 

Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. Blood. 2022;140:1–3.

Article  Google Scholar 

Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cliff ERS, Hilal T, Kesselheim AS. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma. Nat Rev Clin Oncol. 2024;21:1–2.

Article  CAS  PubMed  Google Scholar 

Wang M, Rule S, Zinzani P, et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2020;136:38–9.

Article  Google Scholar 

Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5:2577–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559–63.

Article  CAS  PubMed  Google Scholar 

Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Munoz J, Goy A, et al. KTE-X19 CAR t-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deshpande A, Wang Y, Munoz J, Jain P. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Drugs Today (Barc). 2022;58:283–98.

Article  PubMed  Google Scholar 

Wang M, Munoz J, Goy A, et al. Three-year follow-up of kte-x19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the zuma-2 study. J Clin Oncol. 2023;41:555–67.

Article  CAS  PubMed  Google Scholar 

Jain P, Nastoupil L, Westin J, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021;192:e38–42.

Article  CAS  PubMed  Google Scholar 

Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu S, Blombery P, Westerman D, Tam CS. Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma. Curr Treat Options Oncol 2023.

Hummel M, Tamaru J, Kalvelage B, Stein H. Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle. Blood. 1994;84:403–7.

Article  CAS  PubMed  Google Scholar 

Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771–82.

Article  CAS  PubMed  Google Scholar 

van Dongen JJM, van der Velden VHJ, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996–4009.

Article  PubMed  PubMed Central  Google Scholar 

Drandi D, Alcantara M, Benmaad I, et al. Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network. Hemasphere. 2020;4:e347.

Article  PubMed  PubMed Central  Google Scholar 

Shirai R, Osumi T, Keino D, et al. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma. Int J Hematol. 2023;117:910–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rimokh R, Berger F, Delsol G, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood. 1994;83:1871–5.

Article  CAS  PubMed  Google Scholar 

Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107:2271–8.

Article  CAS  PubMed  Google Scholar 

Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215–23.

Article  CAS  PubMed  Google Scholar 

Bottcher S, Ritgen M, Buske S, et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica. 2008;93:551–9.

Article  PubMed  Google Scholar